Biomarkers for increased risk of drug-induced liver injury from exome sequencing studies
AssigneeSevere Adverse Event (Sae) Consortium
InventorAris FLORATOS
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly Drug-Induced Liver Injury (DILI) or hepatotoxicity. The invention also provides a method of identifying a subject afflicted with, or at risk of, developing DILI. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing DILI.
Claims16
A method of identifying a subject afflicted with, or at risk of developing, Drug-Induced Liver Injury (DILI) comprising:
- (a) obtaining a nucleic-acid containing sample from the subject;
- and
- (b) analyzing the sample to detect the presence of at least one genetic marker, or an equivalent to at least one genetic marker, selected from those in Tables 1, 2, 3, 4, and 6,
- wherein the presence of at least genetic marker, or an equivalent to at least one genetic marker, from Tables 1, 2, 3, 4 and 6 in the sample indicates that the subject is afflicted with, or at risk of, developing DILI.
A method of identifying a drug agent for the treatment of DILI, comprising:
- (a) contacting cells expressing at least one genetic marker from Tables 1, 2, 3, 4, and 6 with a putative drug agent;
- and
- (b) comparing expression of the cells prior to contact with the putative drug agent to expression of the cells after contact with the putative drug agent;
- wherein a decrease in expression of the cells after contact with the putative drug agent identifies the agent as an agent for the treatment of DILI.
Dependencies are inferred from the claim text.